BioCentury | Jan 17, 2018
Distillery Therapeutics

Inflammation

...a CD23-mimicking single-domain antibody against IgE could help treat allergy. The single-domain neutralizing antibody mimics CD23...
...against IgE, to treat chronic idiopathic urticaria (CIU) and allergic asthma. TARGET/MARKER/PATHWAY: Immunoglobulin E (IgE); CD23...
...Aarhus, Denmark email: nsl@mbg.au.dk CONTACT: Edzard Spillner, same affiliation as above email: e.spillner@eng.au.dk Claire Quang Aarhus University Hospital CD23 Immunoglobulin...
BioCentury | Oct 26, 2017
Translation in Brief

An adjuvant to remember

...that binds epitopes on influenza A virus hemagglutinin with one part of the molecule, and CD23...
...in which the Fab domains recognize the antigen, and a sialylated Fc domain engages the CD23...
...or an Fc variant that mimicked sialylation, either of which could bind and recruit high-affinity, CD23-expressing...
BioCentury | Oct 17, 2017
Distillery Therapeutics

Infectious disease

...INDICATION: Influenza virus Mice studies suggest CD23 -activating, bispecific antibodies against two HA epitopes could help...
...Fc domain, or engineered to contain a variant Fc domain that mimics sialylation, to activate CD23...
...A virus HA, in Phase II testing for influenza. TARGET/MARKER/PATHWAY: Influenza A virus hemagglutinin (HA); CD23...
BioCentury | May 21, 2015
Translation in Brief

Formula's Italian CAR

...cells targeting CD19. After CD19, Formula will target CD33 for acute myelogenous leukemia (AML), and CD23...
BioCentury | Jul 21, 2011
Distillery Therapeutics

Indication: Cancer

...Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL); hairy cell leukemia CD160; CD23...
...levels of CD160 diagnosed CLL with 95% specificity and 100% sensitivity, and the ratio of CD23...
BioCentury | Oct 26, 2009
Clinical News

Lumiliximab: Suspended Phase II/III enrollment

...Mass. Product: Lumiliximab (Anti- CD23 mAb) (formerly IDEC-152 ) Business: Cancer Molecular target: CD23 Description: Anti-CD23...
BioCentury | Oct 21, 2009
Company News

Biogen Idec discloses pipeline setbacks

...review of the programs determined that the trials would not support registration of the anti- CD23...
BioCentury | Jun 1, 2009
Regulation

Accelerate, or not

...most common leukemia in the U.S., is characterized by the accumulation of CD5-, CD20- and CD23-positive...
BioCentury | Jan 21, 2008
Clinical News

Lumiliximab regulatory update

...to grant Orphan Drug designation for lumiliximab to treat chronic lymphocytic leukemia (CLL). The anti- CD23...
BioCentury | Feb 12, 2007
Clinical News

Lumiliximab regulatory update

...to treat relapsed or refractory chronic lymphocytic leukemia (CLL). Lumiliximab is a monoclonal antibody against CD23...
Items per page:
1 - 10 of 25